Let’s talk about consolidation in Andromeda’s case is strategic, not a sign of trouble. With 2.5 billion shares on issue, it’s necessary to attract institutional investors, clean up the capital structure, and facilitate future capital raises.
Consolidation doesn’t fix a bad company — it refines the share structure to make it more appealing for larger investors and to better position the stock for upside when the funding and development phases hit full stride.
ADN’s been making real progress — from the DFS in 2023, to the Traxys offtake deal and high-purity alumina breakthroughs. If you’re writing off consolidation as a negative, you’re overlooking the bigger picture.
It’s a tool, not the endgame.
And probably on the cards next
ADN Price at posting:
1.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)